News

Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema ...
Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find ...
Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...
Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...
Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...
Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...
Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...
Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...
Danish group lost €90bn in market capitalisation in December after preliminary results showed it missed its target ...
Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...
Novo Nordisk ends partnership with Hims & Hers over safety and marketing concerns tied to compounded Wegovy, as rivalry with ...
However, negotiations for the EU's pharmaceutical legislation – dubbed the pharma package – were complex, particularly as ...